康希诺：横纹肌肉瘤疫苗已获批IIT

证券之星08-21 18:04

证券之星消息，康希诺(688185)08月21日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘您好，美国Moderna（莫德纳）宣布黑色素瘤皮肤癌疫苗在大型试验中达到目标影响，贵公司mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发进展如何？谢谢！！

康希诺回复：尊敬的投资人您好，公司利用累积的mRNA平台技术，正在推进mRNA疫苗用于治疗横纹肌肉瘤及胶质母细胞瘤等适应症的研发工作，横纹肌肉瘤疫苗已获批IIT，脑胶质瘤疫苗处于IIT获批前阶段，同时会持续布局候选产品线。谢谢！

本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。

责任编辑：刘浩然

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2661758261?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-21 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661758261","market":"sh","top_or_hot":-1,"title":"康希诺：横纹肌肉瘤疫苗已获批IIT","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/688185\">康希诺</a>(688185)08月21日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘您好，美国<a href=\"https://laohu8.com/S/MRNA\">Moderna</a>（莫德纳）宣布黑色素瘤皮肤癌疫苗在大型试验中达到目标影响，贵公司mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发进展如何？谢谢！！</p><p><a href=\"https://laohu8.com/S/06185\">康希诺</a>回复：尊敬的投资人您好，公司利用累积的mRNA平台技术，正在推进mRNA疫苗用于治疗横纹肌肉瘤及胶质母细胞瘤等适应症的研发工作，横纹肌肉瘤疫苗已获批IIT，脑胶质瘤疫苗处于IIT获批前阶段，同时会持续布局候选产品线。谢谢！</p><p>本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。</p><p>责任编辑：刘浩然</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康希诺：横纹肌肉瘤疫苗已获批IIT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康希诺：横纹肌肉瘤疫苗已获批IIT\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-21 18:04 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026082100033267.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，康希诺(688185)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，美国Moderna（莫德纳）宣布黑色素瘤皮肤癌疫苗在大型试验中达到目标影响，贵公司mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发进展如何？谢谢！！康希诺回复：尊敬的投资人您好，公司利用累积的mRNA平台技术，正在推进mRNA疫苗用于治疗横纹肌肉瘤及胶质母细胞瘤等适应症的研发...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026082100033267.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://stock.stockstar.com/RB2026082100033267.shtml","article_id":"2661758261","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661758261","pubTimestamp":1787306644,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，康希诺(688185)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，美国Moderna（莫德纳）宣布黑色素瘤皮肤癌疫苗在大型试验中达到目标影响，贵公司mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发进展如何？谢谢！！康希诺回复：尊敬的投资人您好，公司利用累积的mRNA平台技术，正在推进mRNA疫苗用于治疗横纹肌肉瘤及胶质母细胞瘤等适应症的研发工作，横纹肌肉瘤疫苗已获批IIT，脑胶质瘤疫苗处于IIT获批前阶段，同时会持续布局候选产品线。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","688185":"康希诺","BK0239":"医药制造"},"translate_title":"CanSino: Rhabdomyosarcoma vaccine has been approved for IIT","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1.5,"688185":1.5},"content_text":"证券之星消息，康希诺(688185)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，美国Moderna（莫德纳）宣布黑色素瘤皮肤癌疫苗在大型试验中达到目标影响，贵公司mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发进展如何？谢谢！！康希诺回复：尊敬的投资人您好，公司利用累积的mRNA平台技术，正在推进mRNA疫苗用于治疗横纹肌肉瘤及胶质母细胞瘤等适应症的研发工作，横纹肌肉瘤疫苗已获批IIT，脑胶质瘤疫苗处于IIT获批前阶段，同时会持续布局候选产品线。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661758261","isCrawlerRequest":true}